Category: Uncategorized

The critical sensor failure which occurs during calibration in regulated GMP environments should be treated as a potential compliance risk, not as a standard operational deviation. When calibration results fall outside acceptance limits, an immediate Out-of-Tolerance (OOT) Investigation is required to protect product quality, data integrity, and patient safety. Immediate Actions After an Out-of-Tolerance (OOT) […]

The UK pharmaceutical and life sciences industry requires equipment qualification as an essential component to achieve GMP compliance. Manufacturers deliver equipment together with Factory Acceptance Testing (FAT) and Site Acceptance Testing (SAT) reports. The reports which organizations receive from vendors can bring useful information to their operations. However organizations have to determine the extent to which they can depend on vendor information when […]

The Unique Risk Profile of Disposable Manufacturing Equipment The UK biopharmaceutical industry has undergone a manufacturing revolution because Single-Use Technology (SUT) delivers flexible operational capabilities which enable rapid equipment replacement and complete elimination of cleaning validation procedures. The operational advantages of bioprocessing disposables create operational benefits for companies, which organizations must control through existing SUT risk evaluation […]

The pharmaceutical and life sciences sectors in the UK use experience and instinct for risk assessment through Failure Mode and Effects Analysis (FMEA) when they assign risk scores. The current regulatory framework, together with quantitative risk management principles, now requires organizations to implement data-driven methods. The recent ICH Q9(R1) update requires organizations to conduct risk […]

Why Shallow Assessments are the Leading Cause of Post-Change Deviations The United Kingdom pharmaceutical and life sciences industry requires organizations to use effective change management methods for their compliance with GMP standards. Organizations continue to face post-change deviations because they conduct only basic assessments during their GMP change control procedures. The review process appears to function effectively through its […]

The growing need for drug-device combination products results in unique challenges which need to be solved through regulatory systems. The FDA needs companies to demonstrate their ISO 13485 and GMP compliance through the upcoming 2026 implementation of ISO 13485 for Quality Management System Regulation (QMSR 2026). Drug-device combination manufacturers need to understand the relationship between ISO 13485 and GMP standards to sustain […]

The pharmaceutical and life sciences industries in the UK face mounting difficulties because of climate change, together with specific challenges that affect pharmaceutical logistics operations during extreme temperature and humidity variations, which will occur in 2026. The storage conditions in warehouses must meet compliance standards because they determine product quality, shelf life, and GDP storage requirements. The primary method for protecting […]

Why “ALCOA+” is the #1 Focus for Inspectors This Year Data integrity has become the primary focus of regulatory bodies in 2026, while inspectors use ALCOA+ principles as their primary evaluation standard for pharmaceutical and life sciences operations. The FDA and MHRA require organizations to maintain complete and accurate records, which makes ALCOA+ compliance mandatory […]

The European Union’s Veterinary Good Manufacturing Practice (GMP) framework is undergoing development. The European Union regulation, which establishes requirements for all Marketing Authorisation Holders and manufacturers, will become effective on July 16 2026, according to the veterinary medicinal product regulations defined in Regulation EU 2019/6. UK businesses must understand this roadmap to prepare for their […]